Corcept Therapeutics | CORT - Interest Expense On Debt


Corcept Therapeutics reported $888.7M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alaunos Therapeutics USD 1.07M 215K Jun/2023
ANI Pharmaceuticals USD 3.64M 775K Jun/2026
Ardelyx USD 5.6M 160K Mar/2026
Aurora Cannabis CAD 230K 1.88M Mar/2026
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
J&J USD 43M 25M Mar/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 462M 119M Jun/2026
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 3.62M 77K Jun/2026
Pfizer USD 667M 4M Jun/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
TG Therapeutics USD 16.57M 8.91M Jun/2026